Anthracosis

LONDON, Oct. 10, 2023 /PRNewswire/ -- With widespread population expansion and rapid urbanization, the food and accommodation need of human beings have soared dramatically. This leads to the exploitation of environmental or natural resources. Increasing emission levels from vehicles and factors, deforestation, improper waste management, along with other such activities are resulting in a prompt increase in the amount of environmental toxins. These toxins can cause a wide range of diseases in both human beings and animals. Environmental diseases are generally caused when an individual gets excessively exposed to environmental toxins, contaminants, adverse environmental conditions, and pollutants. According to environmental disease statistics 2023 by the Office of Disease Prevention and Health Promotion, over 12 million people lose their lives every year due to such ailments. This has created a need for proper management of such ailments along with stringent measures to regulate pollution levels. The players operating in this landscape are striving to bring about a transformation in the way such ailments are detected, managed, treated, and prevented. They are collaborating with other organizations and government bodies with an aim to accelerate their R&D endeavours and yield fruitful results. Many such players have sought assistance from Disease Landscape Insights due to its deep dive expertise in the field. This health consultant helps them with treatment gaps identification, clinical trial feasibility analysis, overall clinical trial management, product portfolio analysis, and commercial strategy analysis, among others. DLI has also been accelerating the environmental diseases market growth by empowering players with its comprehensive disease insights. Its vast repository encompasses a vast environmental disease pipeline including- Demodex Blepharitis Silicosis Bronchitis Black Lung Disease Emphysema Dermatitis Allergies and Asthma Others Disease Overview- Characteristics, Symptoms, and Triggering Factors Environmental diseases comprise of broad category of health conditions that are primarily caused or exacerbated by exposure to environmental factors. These factors can either be physical, chemical, biological, or a combination thereof. Such ailments mostly result from long-term or repeated exposure and can affect individuals of all ages. The symptoms of environmental diseases can vary depending on the specific condition and the nature of the environmental exposure. Common symptoms may include respiratory problems (e.g., coughing, wheezing), skin disorders (e.g., rashes, irritation), gastrointestinal issues (e.g., nausea, diarrhea), neurological symptoms (e.g., headaches, confusion), and various other health problems. Environmental diseases are triggered or exacerbated by exposure to various environmental hazards. These triggering factors can include air pollution, water contamination, chemical exposure, radiation exposure, occupational hazards, and climate change. Price and Market Access Diagnostic and treatment landscape The early and accurate detection of such diseases play a vital role in safeguarding the lives of the patients. Medical history and physical examination, blood tests, urine tests, x-rays, MRIs, CT scans, allergy testing, biopsies, and environmental monitoring, among others. Environmental diseases market players are taking extensive efforts to develop effective treatment solutions against such ailments. They are striving to cater to environmental disease unmet needs in terms of detection, management, treatment, and prevention. It is worth noting that the treatment plans for such diseases vary depend on their degree of severity and overall health conditions of the patient. Environmental diseases drugs such as bronchodilators and corticosteroids for asthma, antihistamines for allergies, or chelation therapy for heavy metal poisoning are generally recommended by the doctors. Apart from that allergen-specific immunotherapy (allergy shots) are prescribed in case of allergies. Surgical intervention may also be necessary to remove tumors or damaged tissue caused by environmental factors, such as skin cancer or asbestos-related lung disease. Patients may be advised to make lifestyle changes, such as quitting smoking, adopting a healthier diet, or wearing protective clothing, to reduce the impact of environmental factors on their health. DLI has been assisting these players in their drug development endeavours. From offering them with regulatory consulting services, product development services and new product launch services to post launch services, DLI has been a strong support for them. Pharma consulting Services Final Words Environmental diseases have emerged as a global health concern. Growing emission levels, increased air and water pollution rates, deforestation, and rising worldwide population are significantly leading to environmental degradation. Environmental disease epidemiology studies suggest that a significant portion of the world's population gets exposed to harmful environmental toxins every day. This makes them highly susceptible to environmental ailments. Industry players have joined hands to develop effective diagnostic and treatment solutions for this menace. Many of them have opted for pharma consulting services from DLI to solidify their presence in the global market. DLI has been helping them with product portfolio extension, price reimbursement plans, along with clinical trial assessment activities. The management of environmental diseases often involves a multidisciplinary approach, with healthcare providers, environmental specialists, and public health agencies working together to diagnose, treat, and prevent these conditions. The specific treatment plan should be developed in consultation with a healthcare professional, taking into account the individual patient's condition and needs. About Disease Landscape:  Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to the healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  Contact Us:  Disease Landscape Insights LLP  6th Floor, Sr No.207, Office A H 6070 Phase 1  Solitaire Business Hub, Viman Nagar  Pune, Maharashtra, 411014  Email: [email protected]    Email: [email protected] Sales: +44-2038074155  Asia Office: +917447409162 Blog:   Case Study:    Pharma consulting Services  Follow Us: LinkedIn | Twitter | Facebook Logo: SOURCE Disease Landscape Insights

The U.S. Food and Drug Administration approved Boehringer Ingelheim’s Ofev (nintedanib) for patients with chronic fibrosing interstitial lung diseases with a progressive phenotype. The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim ’s Ofev (nintedanib) for patients with chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype. It is the first drug to be approved in the U.S. for patients with this type of lung disease. The drug was originally approved to treat idiopathic pulmonary fibrosis (IPF) in 2014. Last year it was approved for extended indications with ILD caused by systemic sclerosis (SSC-ILD), which is a rare autoimmune disease affecting about 100,000 people in the U.S. Chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype is a group of fibrotic lung disease—fibrosis refers to scarring—caused by different diseases, including autoimmune ILD, hypersensitivity pneumonitis and idiopathic nonspecific interstitial pneumonia. These diseases are all marked by lung scarring and rapid progression of the disease, which is tested by way of lung function tests, symptoms and potentially imaging. It leads to breathlessness and respiratory failure. It can be both debilitating and life-threatening. “The FDA continues to encourage the development of therapies for patients with limited or no treatment options,” said Banu Karimi-Shah, acting deputy director of the Division of Pulmonary, Allergy, and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research. “Today’s approval helps to fulfill an unmet treatment need, as patients with these life-threatening lung diseases have not had an approved medication until now.” The drug’s safety and effectiveness were studied in a randomized, double-blind, placebo-controlled trial of 663 adult patients with a mean age of 66 years. The primary test for effectiveness was forced vital capacity, a test for lung function. In the year-long trial, patients received 150 mg of Ofev twice a day or a placebo. After the 52 weeks, people taking Ofev had less lung function decline compared to the placebo cohort. The most common side effects were diarrhea, nausea, stomach pain, vomiting, liver problems, decreased appetite, headache and weight loss. The drug is not recommended for patients with moderate or severe liver problems. The new approval applies to about 18% to 32% of patients with about 200 separate diseases, including “unclassifiable ILDs, autoimmune ILDs, chronic hypersensitivity pneumonitis, sarcoidosis, myositis, Sjogren’s syndrome, coal workers pneumoconiosis and idiopathic forms of interstitial pneumonias,” stated Boehringer Ingelheim. At its most severe, ILD can decrease life expectancy by three to five years. Ofev is a blockbuster drug and grew almost 29% to reach 1.1 billion euros in 2018 for IPF. The 2019 financial figures haven’t been reported yet, but in the first half of the year sales grew 22% to 677 million euros. Although Ofev is considered Boehringer’s flagship product for its fibrosis franchise, the company is making significant investments in the category. Earlier this year it signed a multi-billion-euro deal with Enleofen for IL-11 inhibitors for fibrotic disease of the lungs, liver and other organs. Previous deals were signed with Bridge Biotherapeutics for an Ofev follow-up and with South Korea’s Yuhan Corporation on a first-in-class dual agonist for the treatment of non-alcoholic steatohepatitis (NASH) and related liver diseases.